Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6826 to 6840 of 7691 results

  1. Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer after chemotherapy [ID1621]

    Discontinued [GID-TA10492]

    Technology appraisal guidance
    Discontinued

  2. Avelumab for maintenance treatment of advanced gastric or gastro-oesophageal junction cancer after platinum-based chemotherapy [ID2693]

    Discontinued [GID-TA10628]

    Technology appraisal guidance
    Discontinued

  3. Elotuzumab for untreated multiple myeloma [ID966]

    Discontinued [GID-TA10134]

    Technology appraisal guidance
    Discontinued

  4. Nivolumab for treating platinum-resistant advanced or recurrent ovarian cancer [ID2714]

    Discontinued [GID-TA10590]

    Technology appraisal guidance
    Discontinued

  5. Tanezumab for treating pain caused by bone metastases [ID3784]

    Discontinued [GID-TA10922]

    Technology appraisal guidance
    Discontinued

  6. Canakinumab with pembrolizumab and chemotherapy for untreated advanced non-small cell lung cancer with no EGFR or ALK mutations [ID3977]

    Discontinued [GID-TA10857]

    Technology appraisal guidance
    Discontinued

  7. Ovarian (epithelial), fallopian, peritoneal cancer - paclitaxel (encapsulated in XR-17 [ID565]

    Discontinued [GID-TA11209]

    Technology appraisal guidance
    Discontinued

  8. Multiple myeloma (untreated) - carfilzomib (with melphalan and prednisone) [ID1133]

    Discontinued [GID-TA11210]

    Technology appraisal guidance
    Discontinued

  9. Nintedanib for treating fibrosing interstitial lung disease in people aged 6 to 17 [ID6194]

    In development [GID-TA11126] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701

    In development [GID-TA11157] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Hypercholesterolaemia (primary), dyslipidaemia (mixed) - anacetrapib [ID1165]

    Discontinued [GID-TA11175]

    Technology appraisal guidance
    Discontinued

  12. Idasanutlin with cytarabine for treating relapsed or refractory acute myeloid leukaemia [ID1597]

    Discontinued [GID-TA10494]

    Technology appraisal guidance
    Discontinued

  13. Entinostat for treating hormone receptor-positive breast cancer after hormonal therapy [ID1260]

    Discontinued [GID-TA10309]

    Technology appraisal guidance
    Discontinued

  14. Nivolumab with ipilimumab for neoadjuvant treatment of early non-small-cell lung cancer [ID3756]

    Discontinued [GID-TA10631]

    Technology appraisal guidance
    Discontinued

  15. Empagliflozin for type 1 Diabetes Mellitus, adjunct to insulin ID1275

    Discontinued [GID-TA10375]

    Technology appraisal guidance
    Discontinued